Brief Description

Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
Target: Kit; PDGFRβ; VEGFR2
References on Toceranib:
[1]. Yancey MF, et al. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.J Vet Pharmacol Ther. 2010 Apr;33(2):162-71.
[2]. Leblanc AK, et al. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.Vet Radiol Ultrasound. 2012 May-Jun;53(3):348-57.
[3]. London C, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(?) ) in solid tumours.Vet Comp Oncol. 2012 Sep;10(3):194-205.

Solubility

10 mM in DMSO

Melting point

Boiling point

Density

Formula Weight:

Flash point

Storage conditions

Store at -20°C 2 years

Appearance:

Light yellow to yellow solid